N-[(3-chloro-2-methylphenyl)methyl]-2-[2-(2,4-difluorophenyl)-3-methylimidazol-4-yl]acetamide | 1245816-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[(3-chloro-2-methylphenyl)methyl]-2-[2-(2,4-difluorophenyl)-3-methylimidazol-4-yl]acetamide
• CAS: 1245816-59-4
• 化学式: C₂₀H₁₈ClF₂N₃O
• 分子量: 389.832
• InChiKey: WRPHYPFMMUAFAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  、 3-氯-2-甲基苄胺 在 N-乙基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 N-[(3-chloro-2-methylphenyl)methyl]-2-[2-(2,4-difluorophenyl)-3-methylimidazol-4-yl]acetamide
  参考文献：
  名称：

  Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X7 antagonists

  摘要：

  A series of analogues of the pyrazole lead 1 were synthesized in which the heterocyclic core was replaced with an imidazole. A number of potent antagonists were identified and structure-activity relationships (SAR) were investigated both with respect to activity at the P2X(7) receptor and in vitro metabolic stability. Compound 10 was identified as a potent P2X(7) antagonist with reduced in vitro metabolism and high solubility. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.05.018

文献信息

• Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X7 antagonists
  作者：Robert J. Gleave、Daryl S. Walter、Paul J. Beswick、Elena Fonfria、Anton D. Michel、Shilina A. Roman、Sac-Pham Tang

  DOI：10.1016/j.bmcl.2010.05.018

  日期：2010.8

  A series of analogues of the pyrazole lead 1 were synthesized in which the heterocyclic core was replaced with an imidazole. A number of potent antagonists were identified and structure-activity relationships (SAR) were investigated both with respect to activity at the P2X(7) receptor and in vitro metabolic stability. Compound 10 was identified as a potent P2X(7) antagonist with reduced in vitro metabolism and high solubility. (c) 2010 Elsevier Ltd. All rights reserved.